Malignant mesothelioma after radiation treatment for Hodgkin lymphoma

Blood

Volumn 113, Issue 16, 2009, Pages 3679-3681

  De Bruin, Marie L ^a   Burgers, Jacobus A ^a   Baas, Paul ^a   Van't Veer, Mars B ^b   Noordijk, Evert M ^c   Louwman, Marieke W J ^d   Zijlstra, Josée M ^e   Van Den Berg, Hendrik ^f   Aleman, Berthe M P ^a   Van Leeuwen, Flora E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Erasmus University Rotterdam and Eindhoven Cancer Registry   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS;

ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; HISTOLOGY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; MESOTHELIOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RADIATION INJURY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SURVIVAL RATE;

EID: 65549109939     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-184705     Document Type: Article

References (20)

1. Zucali PA, Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer. 2006;42:2706-2714. (Pubitemid 44584672)
2. Huncharek M. Non-asbestos related diffuse malignant mesothelioma. Tumori. 2002;88:1-9. (Pubitemid 34269790)
3. Cavazza A, Travis LB, Travis WD, et al. Post-irradiation malignant mesothelioma. Cancer. 1996;77:1379-1385.
4. Warren S, Brown CE, Chute RN, Federman M. Mesothelioma relative to asbestos, radiation, and methylcholanthrene. Arch Pathol Lab Med. 1981;105:305-312. (Pubitemid 11047797)
5. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40 576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97:1354-1365.
6. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25:1489-1497. (Pubitemid 46759253)
7. Teta MJ, Lau E, Sceurman BK, Wagner ME. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer. 2007;109:1432-1438. (Pubitemid 46466572)
8. Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107:108-115. (Pubitemid 43939037)
9. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21:3431-3439. (Pubitemid 46603515)
10. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol. 1994;12:312-325. (Pubitemid 24056405)
11. van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18:487-497. (Pubitemid 30078530)
12. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878-1886. (Pubitemid 46348183)
13. World Health Organization. International Classification of Diseases for Oncology, 3rd Ed. Geneva, Switzerland: World Health Organization; 2000.
14. Janssen-Heijnen ML, Damhuis RA, Klinkhamer PJ, Schipper RM, Coebergh JW. Increased but low incidence and poor survival of malignant mesothelioma in the southeastern part of The Netherlands since 1970: a population-based study. Eur J Cancer Prev. 1999;8:311-314.
15. Netherlands Cancer Registry. Cancer in figures: Association of Comprehensive Cancer Centres. http://www.ikcnet.nl. Accessed October 1, 2008.
16. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J. Natl Cancer Inst. 2002;94:182-192. (Pubitemid 34162752)
17. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst. 1995;87:1530-1537.
18. Peterson JT Jr, Greenberg SD, Buffler PA. Non-asbestos-related malignant mesothelioma: a review. Cancer. 1984;54:951-960.
19. Altomare DA, Vaslet CA, Skele KL, et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res. 2005;65:8090-8095.
20. Hei TK, Geard CR, Osmak RS, Travisano M. Correlation of in vitro genotoxicity and oncogenicity induced by radiation and asbestos fibres. Br J Cancer. 1985;52:591-597. (Pubitemid 16221581)